DK0773025T3 - Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling - Google Patents

Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling

Info

Publication number
DK0773025T3
DK0773025T3 DK96901349T DK96901349T DK0773025T3 DK 0773025 T3 DK0773025 T3 DK 0773025T3 DK 96901349 T DK96901349 T DK 96901349T DK 96901349 T DK96901349 T DK 96901349T DK 0773025 T3 DK0773025 T3 DK 0773025T3
Authority
DK
Denmark
Prior art keywords
preparation
acid
formulations containing
benzimidazole compounds
new stable
Prior art date
Application number
DK96901349T
Other languages
Danish (da)
English (en)
Inventor
Rodes Montserrat Ballester
Boven Marinus Van
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0773025(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of DK0773025T3 publication Critical patent/DK0773025T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK96901349T 1995-02-01 1996-01-26 Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling DK0773025T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
PCT/ES1996/000013 WO1996023500A1 (fr) 1995-02-01 1996-01-26 Nouvelles formulations galeniques stables comprenant un compose de benzimidazole acide-labile, et procede de production

Publications (1)

Publication Number Publication Date
DK0773025T3 true DK0773025T3 (da) 2000-10-09

Family

ID=8289322

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96901349T DK0773025T3 (da) 1995-02-01 1996-01-26 Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling
DK99116334T DK0993830T3 (da) 1995-02-01 1996-01-26 Nye stabiliserede galeniske formuleringer indeholdende en syrelabil benzimidazolforbindselse og fremgangsmåde til fremstilling heraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99116334T DK0993830T3 (da) 1995-02-01 1996-01-26 Nye stabiliserede galeniske formuleringer indeholdende en syrelabil benzimidazolforbindselse og fremgangsmåde til fremstilling heraf

Country Status (20)

Country Link
US (1) US5626875A (fr)
EP (2) EP0773025B1 (fr)
JP (1) JP4183746B2 (fr)
KR (1) KR100331290B1 (fr)
AR (1) AR002702A1 (fr)
AT (2) ATE292967T1 (fr)
AU (1) AU4540396A (fr)
CA (1) CA2184842C (fr)
DE (3) DE69634613T2 (fr)
DK (2) DK0773025T3 (fr)
ES (3) ES2094694B1 (fr)
FI (1) FI121730B (fr)
HU (1) HU229219B1 (fr)
IL (1) IL116673A (fr)
IN (1) IN186596B (fr)
PT (2) PT993830E (fr)
SI (2) SI0773025T1 (fr)
TW (1) TW503115B (fr)
WO (1) WO1996023500A1 (fr)
ZA (1) ZA96683B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DK1092434T3 (da) * 1995-09-21 2004-07-26 Pharma Pass Ii Llc Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
AU772726B2 (en) * 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2244167T3 (es) * 1999-12-16 2005-12-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Nuevas preparaciones farmaceuticas multiunitarias estables que contienen bencimidazoles sustituidos.
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
BR0115206A (pt) * 2000-11-10 2003-10-07 Hoffmann La Roche Composições hidroliticamente instáveis
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
US6919459B2 (en) 2001-07-16 2005-07-19 Rudy Laurent Maria Broeckx Process for preparing benzimidazole-type compounds
EP1429746B1 (fr) * 2001-09-28 2008-08-13 McNEIL-PPC, INC. Forme pharmaceutique comprenant un noyau interne et une coque externe
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
CA2494716A1 (fr) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Preparation pharmaceutique contenant un compose de benzimidazole melange a de la cellulose microcristalline et procede pour sa preparation
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1594479A1 (fr) * 2003-01-31 2005-11-16 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazole et leurs procedes de preparation
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
WO2004091622A1 (fr) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Utilisation d'antagonistes des opioides peripheriques, en particulier de methylnaltrexone, dans le traitement du syndrome du colon irritable
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
AU2003245033A1 (en) * 2003-05-08 2004-11-26 Podili Khadgapathi An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
AU2003272086A1 (en) * 2003-10-14 2005-04-27 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
RS52233B (en) 2004-05-07 2012-10-31 Nycomed Gmbh THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006067599A2 (fr) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazoles et leur procede de preparation
WO2006066932A1 (fr) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Composition pharmaceutique stable comprenant une substance active sous la forme d’une solution solide
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
JP2008528497A (ja) * 2005-01-20 2008-07-31 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (fr) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Nouvelles compositions galéniques stabilisées comprenant du lanzoprazole et leur préparation
EP1813275A1 (fr) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Comprime oral desintegrable de lansoprazole
CA2633825A1 (fr) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Comprimes de lansoprazole se desintegrant oralement
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
ES2570374T3 (es) * 2007-03-29 2016-05-18 Progenics Pharm Inc Antagonistas del receptor opioide periférico y usos de los mismos
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2009099411A1 (fr) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009117669A2 (fr) 2008-03-21 2009-09-24 The University Of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
EP2306829B1 (fr) 2008-07-01 2017-01-04 University of Chicago Particules contenant un antagoniste périphérique de récepteur d'opioïde
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
EP2313088A2 (fr) * 2008-08-11 2011-04-27 Mepha GmbH Formulation pharmaceutique orale pour l oméprazole comprenant une couche de séparation spécifique
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
WO2010117756A2 (fr) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Formulations pharmaceutiques de benzimidazole substitué
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
BR112014009580B1 (pt) * 2011-11-02 2022-03-29 Esteve Pharmaceuticals, S.A Composição farmacêutica de omeprazol
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
WO2016061531A1 (fr) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Utilisation de méthylnaltrexone pour atténuer une progression de tumeur
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (fr) 2016-09-07 2018-03-14 Sandoz Ag Formulations d'oméprazole

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
SI0993830T1 (en) 2005-10-31
PT993830E (pt) 2005-06-30
ES2094694A1 (es) 1997-01-16
DE29623938U1 (de) 2000-10-05
ATE292967T1 (de) 2005-04-15
FI963916A (fi) 1996-09-30
HUP9603014A3 (en) 2000-12-28
EP0773025A1 (fr) 1997-05-14
ATE193649T1 (de) 2000-06-15
JP4183746B2 (ja) 2008-11-19
ES2148725T3 (es) 2000-10-16
SI0773025T1 (en) 2000-10-31
EP0773025B1 (fr) 2000-06-07
JPH09511257A (ja) 1997-11-11
CA2184842A1 (fr) 1996-08-08
IL116673A (en) 2000-10-31
HUP9603014A2 (hu) 1998-03-30
ES2094694B1 (es) 1997-12-16
DE69608767D1 (de) 2000-07-13
FI963916A0 (fi) 1996-09-30
HU229219B1 (en) 2013-09-30
IN186596B (fr) 2001-10-06
CA2184842C (fr) 2007-08-07
WO1996023500A1 (fr) 1996-08-08
FI121730B (fi) 2011-03-31
EP0993830A3 (fr) 2001-10-04
PT773025E (pt) 2000-10-31
DE69634613D1 (de) 2005-05-19
DE69634613T2 (de) 2006-03-09
DK0993830T3 (da) 2005-08-08
IL116673A0 (en) 1996-05-14
EP0993830A2 (fr) 2000-04-19
US5626875A (en) 1997-05-06
TW503115B (en) 2002-09-21
AU4540396A (en) 1996-08-21
KR100331290B1 (ko) 2002-11-22
ZA96683B (en) 1997-09-23
ES2238796T3 (es) 2005-09-01
EP0993830B1 (fr) 2005-04-13
AR002702A1 (es) 1998-04-29

Similar Documents

Publication Publication Date Title
DK0773025T3 (da) Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
IT1285387B1 (it) Dispositivo e procedimento per la somministrazione transdermica mediante elettrotrasporto di fentanil e sufentanil.
NO996433L (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
IS2058B (is) Ný taxóíð, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þau
IS1850B (is) Kristölluð a-fjölgervingsmynd af indól afleiðu, notkun hennar, aðferð til framleiðslu og lyfjaefnablanda
IS6197A (is) Aðferð og búnaður til að koma lyfjablöndum á úðaform
IS4311A (is) Setin 1H-imíðazól, aðferð til framleiðslu þeirra og notkun þeirra
IS1846B (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
FI931916A0 (fi) Transdermala befruktningshindrande formuleringar, metoder och anordningar
IT1284243B1 (it) Procedimento ed apparecchio per la comunicazione di messaggi
IS4635A (is) 4-fenýlamínóþíasólafleiður, aðferð við að framleiða þær og lyfjablöndur sem innihalda þær
RS50245B (sr) Gastroprotektovane mikrogranule omeprazola, postupak za proizvodnju i farmaceutski preparati
DK0861588T3 (da) Fremgangsmåde til sterilisering af jord og tilhørende udstyr
IT1285398B1 (it) Dispositivo e procedimento per la somministrazione transdermica mediante elettrotrasporto di fentanil e sufentanil.
NO992408D0 (no) FremgangsmÕte for lavavfalls fremstilling av skiveformige formlegemer inneholdende aktive ingredienser, og transdermale terapeutiske systemer inneholdende samme
DK35087A (da) Hidtil ukendte alkan- og alkoxyalkanderivater, fremgangsmaade til fremstilling deraf og insekticide og akaricide midler indeholdende disse
EE04154B1 (et) Omeprasooli valmistamise meetod
NO306932B1 (no) Oljeaktig preparat og fremgangsmåte for fremstilling av dette
DK1178799T3 (da) Gastrobeskyttede mikrogranula, fremgangsmåde til opnåelse af samme og farmaceutiske præparater
DK0821680T3 (da) Nye taxoider, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
DK0970077T3 (da) Forbedret fremgangsmåde til fremstilling af thiazolidindioner og nye thiazolidindioner
NO932912D0 (no) Preparat og fremgangsmaater til generering av ben
DE59606190D1 (de) Stabile festformulierungen von cyclohexenonoximether-herbiziden
NO308004B1 (no) Nye aminofenylfosfonsyreforbindelser og farmasøytiske sammensetninger inneholdende dem